The PE Ratio as of December 2024 (TTM) for Novo Nordisk A/S (NVO) is 29.62

According to Novo Nordisk A/S’s latest financial reports and current stock price. The company's current PE Ratio is 29.62. This represents a change of -26.62% compared to the average of 40.36 of the last 4 quarters.

Novo Nordisk A/S (NVO) Historical PE Ratio (quarterly & annually)

How has NVO PE Ratio performed in the past?

The mean historical PE Ratio of Novo Nordisk A/S over the last ten years is 27.14. The current 29.62 PE Ratio has changed 10.81% with respect to the historical average. Over the past ten years (40 quarters), NVO's PE Ratio was at its highest in in the June 2024 quarter at 55.84. The PE Ratio was at its lowest in in the March 2017 quarter at 14.74.

Novo Nordisk A/S (NVO) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Novo Nordisk A/S PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Novo Nordisk A/S (NVO) Average PE Ratio

How has NVO PE Ratio performed in the past?

The current PE Ratio of Novo Nordisk A/S (NVO) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Novo Nordisk A/S (NVO) PE Ratio vs. Peers

How is NVO’s PE Ratio compared to its peers?

Novo Nordisk A/S’s PE Ratio is greater than Regeneron Pharmaceuticals, Inc. (16.59), greater than CRISPR Therapeutics AG (-14.56), less than Sarepta Therapeutics, Inc. (95.43), greater than Intellia Therapeutics, Inc. (-2.33), greater than Moderna, Inc. (-6.97), greater than CureVac N.V. (5.83), greater than Novavax, Inc. (-4.78), greater than CohBar, Inc. (-0.15), greater than Reata Pharmaceuticals, Inc. (-20.07), greater than BioNTech SE (-56.31), greater than Ginkgo Bioworks Holdings, Inc. (-0.75), greater than Vertex Pharmaceuticals Incorporated (-219.49), less than BioMarin Pharmaceutical Inc. (39.37), greater than Seagen Inc. (-100.71), greater than Alnylam Pharmaceuticals, Inc. (-94.14), greater than Madrigal Pharmaceuticals, Inc. (-13.08), greater than Intercept Pharmaceuticals, Inc. (-91.78), greater than TG Therapeutics, Inc. (-324.87), greater than Terns Pharmaceuticals, Inc. (-5.12), greater than Hepion Pharmaceuticals, Inc. (-0.15),

Build a custom stock screener for Novo Nordisk A/S (NVO) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Novo Nordisk A/S using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Novo Nordisk A/S (NVO) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Novo Nordisk A/S or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.